E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Rather than relying on a single technique, many mental health professionals are adopting an integrative approach to trauma care that combines modalities such as somatic therapy, mindfulness-based practices and traditional psychotherapy.
imphoenix82
Redcliffe Labs has acquired Pune-based Megavision Diagnostics Center, strengthening its presence in Western India and expanding its integrated diagnostics capabilities by bringing advanced imaging and pathology services under a single network. The acquisition adds two MRI-equipped centres in Pune’s Pimpri-Chinchwad area to Redcliffe’s existing pathology network, enabling patients to access a more comprehensive range of […]
imphoenix82
Dementia research: The collaboration is being led and coordinated by Prema Cognition, in partnership with researchers at the University of Cambridge Memory Lab and clinicians at Fortis Hospitals.
imphoenix82
Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta while Innovent Biologics holds sole commercialization rights for Vanflyta in China.
imphoenix82
A report, jointly developed by Praxis Global Alliance and FICCI, identified five priorities for accelerating AI-enabled MedTech adoption in India.
imphoenix82
Under the agreement, Innate Pharma will conduct the TELLOMAK-3 Phase 3 trial in cutaneous T-cell lymphoma (CTCL), while Sobi will receive exclusive global commercialisation rights for lacutamab following a potential accelerated approval.
imphoenix82
The pharma secretary said developing a strong component industry is essential for India to cater to the global medical device market.
dineshwori
Tudriqev is approved for use in combination with nivolumab to treat adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1-based regimen.
imphoenix82
Energenesis and Taiwan Tanabe will collaborate on process technology transfer and manufacturing and controls (CMC) activities to support a potential New Drug Application (NDA) for ENERGI-F703DFU, investigational topical drug for diabetic foot ulcers, in Taiwan.
imphoenix82
The approval makes Yochanra the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
